CTLA4 and non-small cell lung carcinoma: High levels of CTLA4 and PD-1 expressions on TILs were reported in a study comparing NSCLC and healthy individuals [91], therefore monoclonal antibodies targeting these receptors are the main subject in immunotherapy against NSCLC.